Homology Medicines Inc.

NASDAQ: FIXX · Real-Time Price · USD
0.93
0.00 (0.26%)
At close: Mar 25, 2024, 9:00 PM

Homology Medicines Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
-1.42M n/a 1.42M 1.77M 2.57M 1.96M 2.76M 3.21M 3.21M 3.21M 4.08M 5.47M 33.97M 34.15M 33.04M 31.42M
Cost of Revenue
1.42M 2.71M 1.42M 1.99M 2.57M 1.92M 2.42M 2.64M 2.05M 1.42M 786K n/a n/a n/a n/a n/a
Gross Profit
5K 136K -5K -215K n/a 38K 341K 567K 1.15M 1.79M 3.3M 5.47M 33.97M 34.15M 33.04M 31.42M
Operating Income
-56.73M -53.91M -74.07M -86.07M -98.74M -123.82M -125.68M -123.17M -133.28M -132.41M -130.21M -132.46M -95.95M -92.13M -89.74M -94.88M
Interest Income
-2.6M -1.42M 2.6M 4.11M 5.58M 5.86M 5.7M 4.67M 3.23M 1.82M 601K 179K 185K 154K 142K 447K
Pretax Income
-42.98M -34.1M -48.12M -59.83M -87.08M -117.96M -119.98M -118.51M 1.2M 654K 1.64M -1.03M -95.76M -91.97M -89.6M -94.44M
Net Income
-25.62M -30.71M -65.64M -83.09M -112.96M -129.78M -128.37M -121.06M -108K -753K 186K -2.59M -95.76M -91.97M -89.6M -94.44M
Selling & General & Admin
16.36M 19.16M 24.21M 27.93M 31.26M 31.5M 32.47M 32.32M 38.14M 40.77M 41.31M 42.32M 36.84M 33.64M 33.71M 33.46M
Research & Development
50.58M 44.97M 43.22M 51.85M 62M 87.64M 95.97M 94.07M 98.35M 94.85M 92.98M 95.6M 93.08M 92.63M 89.06M 92.84M
Other Expenses
n/a 2.69M 9.33M 9.33M 9.33M 6.64M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
66.94M 64.13M 74.07M 86.43M 99.9M 125.78M 128.44M 126.38M 136.49M 135.62M 134.29M 137.92M 129.92M 126.28M 122.78M 126.3M
Interest Expense
-1.47M n/a 1.47M 1.47M 1.47M n/a 1.27M 1.74M 1.77M 1.77M 506K 32K n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
37.32M 46.74M 55.26M 86.43M 99.9M 125.78M 128.44M 126.38M 136.49M 135.62M 134.29M 137.92M 129.92M 126.28M 122.78M 126.3M
Income Tax Expense
-17.36M -3.4M 17.52M 23.25M 25.88M 11.82M 8.39M 2.55M 715K 816K 862K 967K n/a n/a n/a n/a
Shares Outstanding (Basic)
12.2M 9.32M 5.16M 995.28K 322.32K 321.41K 321.08K 320.65K 319.35K 317.57K 316.87K 318.22K 316.78K 314.9K 313.79K 279.8K
Shares Outstanding (Diluted)
12.2M 9.66M 6M 2.33M 322.32K 321.41K 321.08K 320.65K 319.35K 319.15K 318.81K 321.53K 317.26K 317.26K 313.87K 279.8K
EPS (Basic)
-3.07 -52.18 -154.92 -260.65 -351.64 -404.77 -401.58 -379.95 -0.55 -3.42 -1.28 -10.97 -304.24 -316.8 -331.96 -375.47
EPS (Diluted)
-3.19 -52.3 -155.03 -261.24 -351.64 -404.77 -401.09 -378.92 -2.5 -5.21 -2.84 -13.04 -303.33 -316.05 -331.93 -375.47
EBITDA
-63.12M -52.16M -52.51M -64.29M -76.73M -109.67M -124.31M -121.69M -132.02M -129.38M -125.71M -126.18M -87.6M -83.79M -81.49M -86.97M
EBIT
-14.16M -14.84M -15.53M -46.34M -59.01M -93.14M -123.47M -120.01M 1.2M 2.39M 2.05M -1.14M -95.95M -92.13M -89.74M -94.88M
Depreciation & Amortization
-179.81K -136K 208.81K 425.81K 621.81K 874K 1.06M 1.17M -129.96M -128.18M -126.4M -124.63M 8.35M 8.34M 8.25M 7.92M